New drug KHN922 enters human trials for hard-to-treat cancers
Disease control
Not yet recruiting
This early-stage study tests a new drug, KHN922, in 276 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants receive the drug by IV and are mo…
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC